Literature DB >> 7305297

Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations.

R S Tindall.   

Abstract

The titer and characteristics of antiacetylcholine receptor antibody (AChR-Ab) were investigated in 184 patients with myasthenia gravis. Mean AChR-Ab titers of each clinical grade increased with the severity of the disease. AChR-Ab was always of an IgG class. IgM (5 of 92) and IgA (2 of 48) class AChR-Ab were detected, but only concurrently with IgG and in low concentrations. IgG subclass 3 was not prominent. In 3 patients with AChR-Ab titers in the normal range, blockade of bungarotoxin binding to receptor could still be demonstrated. AChR-Ab from 6 patients was heterogeneous in affinity for receptor, reactivity from human ocular and gastrocnemius muscle, and blockade ot toxin binding. AChR-Ab was oligoclonal in 4 of 6 patients, as shown by concurrent production of AChR-Ab IgG of both kappa and lambda types. Amniotic fluid and fetal cord serum did not interfere with antibody-receptor interaction. Variation in the pattern of weakness among patients was a function of both the heterogeneity of AChR antibodies and the antigenic uniqueness of receptor complexes from different human muscles.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7305297     DOI: 10.1002/ana.410100506

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

3.  Both binding and blocking antibodies correlate with disease severity in myasthenia gravis.

Authors:  Sa-Yoon Kang; Jung-Hwan Oh; Sook Keun Song; Jung Seok Lee; Jay Chol Choi; Ji-Hoon Kang
Journal:  Neurol Sci       Date:  2015-05-12       Impact factor: 3.307

4.  Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.

Authors:  A Rødgaard; F C Nielsen; R Djurup; F Somnier; S Gammeltoft
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

Review 5.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

6.  [Heterogeneity of acetylcholine receptor antibodies in patients with myasthenia gravis].

Authors:  I Kalies; F Heinz; W P Kaschka; K F Druschky; J R Kalden
Journal:  Klin Wochenschr       Date:  1984-04-16

7.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

Authors:  A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

8.  Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

Review 9.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

10.  Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.